Blog
RSS FeedPosted by Michael Wonder on 05 Aug 2016
PBAC post-market reviews of chronic obstructive pulmonary disease medicines and ezetimibe
5 August 2016 - The public submission process is now closed. ...
Posted by Michael Wonder on 02 May 2016
Umeclidinium for symptom relief in COPD: additional benefit is not proven
2 May 2016 - No sighificant differences for moderate disease and no data for severe disease. ...
Posted by Michael Wonder on 04 Mar 2016
Post-market reviews of COPD medicines and ezetimibe – public consultation
4 March 2016 - The public submission process is now open for the Post-market Reviews of ezetimibe and medicines for COPD. The ...
Posted by Michael Wonder on 01 Mar 2016
New Zealand Pharmaceutical Schedule - 1 March 2016 update
1 March 2016 - the March 2016 issue of the Schedule sees the listing of a number of new medicines/combination ...
Posted by Michael Wonder on 12 Feb 2016
Approval of amendments to the listing of some respiratory products
12 February 2016 - PHARMAC is pleased to announce the approval of amendments to existing listing agreements with Novartis New Zealand ...
Posted by Michael Wonder on 09 Feb 2016
More treatments funded by PHARMAC for respiratory disease
9 February 2016 - PHARMAC is funding six new medicines that will improve treatment options for people with chronic obstructive pulmonary ...
Posted by Michael Wonder on 16 Jan 2016
Aclidinium bromide in COPD: evidence of significant additional value in certain patients
15 January 2016 - With reference to new scientific evidence, the manufacturer requested a reassessment and submitted a new dossier. ...
Posted by Michael Wonder on 19 Nov 2015
Tiotropium/olodaterol in COPD: IQWiG finds disadvantages in patients with more severe disease, advantages for some women
16 November 2015 - According to the findings, there were no statistically significant differences between the treatment groups for the totality ...
Posted by Michael Wonder on 16 Oct 2015
Post-market reviews of medicines to treat COPD and ezetimibe
16 October 2015 - The public submission process for the post-market reviews of chronic obstructive pulmonary disease medicines and ezetimibe are ...